Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News LadRx Corp LADX

LadRx Corp is a biopharmaceutical research and development company specializing in oncology. The Company focuses on the discovery, research and clinical development of anti-cancer drug candidates that employ technologies that target chemotherapeutic drugs to solid tumors and reduce off-target toxicities. The Company’s linker activated drug release (LADR) technology platform consists of an... see more

Recent & Breaking News (OTCQB:LADX)

CytRx to Present at the 18th Annual BIO CEO & Investor Conference

PR Newswire February 1, 2016

CytRx Corporation Appoints Olivia Ware as Chief Commercial Officer

PR Newswire January 11, 2016

CytRx Announces Settlement of California Stockholder Derivative Lawsuit

PR Newswire January 5, 2016

The Road Ahead - New Reports on AppFolio, CytRx, USA Truck and Egalet

Accesswire December 17, 2015

CytRx Announces Settlement of the Consolidated Securities Class Action Lawsuit

PR Newswire December 10, 2015

CytRx Nominates Next Clinical Drug Candidate DK049

PR Newswire December 7, 2015

CytRx Announces Participation at the 26th Annual Oppenheimer Healthcare Conference

PR Newswire December 3, 2015

CytRx Announces the Completion of Enrollment in Pivotal Global Phase 3 Trial Ahead of Schedule

PR Newswire December 1, 2015

Aldoxorubicin Continues To Demonstrate Positive Clinical Activity In Phase 2 Glioblastoma Trial

PR Newswire November 23, 2015

CytRx Reports 2015 Third Quarter Financial Results

PR Newswire November 3, 2015

CytRx to Present Additional Data from its Phase 1b/2 Clinical Trial Combining Aldoxorubicin with Ifosfamide/Mesna at the CTOS 2015 Annual Meeting

PR Newswire October 28, 2015

CytRx Announces the Publication of its Positive Global Phase 2b Clinical Trial Results for Soft Tissue Sarcoma in the Peer-Reviewed JAMA Oncology

PR Newswire September 21, 2015

CytRx Announces the Presentation of its Phase 2b Clinical Trial Design in Small Cell Lung Cancer at the World Conference on Lung Cancer in Denver, Colorado

PR Newswire September 3, 2015

CytRx Announces Participation at FBR & Co. Second Annual Health Conference and Rodman & Renshaw 17th Annual Global Investment Conference

PR Newswire September 1, 2015

CytRx Reports 2015 Second Quarter Financial Results

PR Newswire August 3, 2015

CytRx Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

PR Newswire July 24, 2015

The Biotech Rocket is Running Out of Fuel: Three Stocks to Keep You Soaring - Broad Street Alerts

Accesswire July 23, 2015

The Biotech Rocket is Running Out of Fuel: Three Stocks to Keep You Soaring - Broad Street Alerts

Accesswire July 23, 2015

CytRx Announces Pricing of Public Offering of 9.1 Million Shares of Common Stock

PR Newswire July 21, 2015

CytRx Announces Proposed Public Offering of Common Stock

PR Newswire July 20, 2015